Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

PerspectiveFree Preview

Where Were the Women? Gender Parity in Clinical Trials

List of authors.
  • Robert H. Goldstein, M.D., Ph.D.,
  • and Rochelle P. Walensky, M.D., M.P.H.

On October 3, the FDA approved coformulated tenofovir alafenamide and emtricitabine (F/TAF) for HIV prevention in at-risk “adults and adolescents…excluding those who have receptive vaginal sex.” F/TAF’s story highlights numerous flaws in the drug-approval process.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available at NEJM.org.

This article was published on October 30, 2019, at NEJM.org.

Author Affiliations

From the Division of Infectious Diseases, Department of Medicine (R.H.G., R.P.W.), and the Medical Practice Evaluation Center (R.P.W.), Massachusetts General Hospital, and the Harvard University Center for AIDS Research, Harvard Medical School (R.P.W.) — both in Boston.

Print Subscriber? Activate your online access.